FDA Limits Use of Sotrovimab to Treat Covid-19 Due to BA.2 Omicron Subordinated-variant
March 25 2022 - 4:57PM
Dow Jones News
By Maria Armental
GlaxoSmithKline PLC and Vir Biotechnology Inc.'s sotrovimab is
no longer authorized to treat Covid-19 in Connecticut, New York,
New Jersey and other states, because it's unlikely to be effective
against the Omicron BA.2 sub-variant, federal health regulators
said.
The Food and Drug Administration said that latest data indicates
that the authorized dose of sotrovimab is unlikely to be effective
against the surging sub-variant and said that its use is no longer
authorized in areas where the sub-variant is estimated to account
for more than 50% of cases. That includes Connecticut, Maine,
Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey,
New York, Puerto Rico and the U.S. Virgin Islands.
The companies said they are preparing a package of data
supporting a higher dose.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
March 25, 2022 16:42 ET (20:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
